Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
709 stopped studies mapped to Hepatopancreatobiliary Carcinoma and descendants · 93% state a reason
Over the 709 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06337162 | Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)(HCC) | Phase 1 | withdrawn | Mar 29, 2024 | Abramson Cancer Center at Penn Medicine | Incyte made a strategic business decision to stop enrollment to all ongoing oral PD-L1 (99280)… | Enrollment / accrual |
| NCT04497038 | Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B… | Phase 1 / Phase 2 | terminated | Aug 4, 2020 | University of Michigan Rogel Cancer Center | loss of funding | Funding |
| NCT04931420 | Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive… | Phase 2 | withdrawn | Jun 18, 2021 | University of Chicago | PI left site | Investigator |
| NCT04212221 | MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in… | Phase 1 / Phase 2 | terminated | Dec 26, 2019 | Zai Lab (Shanghai) Co., Ltd. | Due to the rapid shifting of liver cancer disease landscape and the company's adjustment of… | Sponsor / business decision |
| NCT06398587 | Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of… | Phase 2 | withdrawn | May 3, 2024 | OHSU Knight Cancer Institute | Sponsor withdrawal | Other (stated, no rule matched) |
| NCT03956056 | Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical… | Phase 1 | terminated | May 20, 2019 | Washington University School of Medicine | Insufficient funding/staff | Funding |
| NCT02314052 | Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular… | Phase 1 / Phase 2 | terminated | Dec 10, 2014 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Sponsor decision | Sponsor / business decision |
| NCT02649868 | LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of… | N/A | terminated | Jan 8, 2016 | National Institutes of Health Clinical Center (CC) | unavailability of study device | Other (stated, no rule matched) |
| NCT05009953 | Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer | Phase 2 | terminated | Aug 18, 2021 | CSPC Ouyi Pharmaceutical Co., Ltd. | Internal strategy change. Not related to safety concerns. | Safety / toxicity |
| NCT05769959 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | Phase 1 | terminated | Mar 15, 2023 | Hoffmann-La Roche | Sponsor decision (not related to safety, efficacy or quality). | Safety / toxicity |
| NCT04833959 | Pilot Study of 89-Zr Panitumumab in Pancreas Cancer | Phase 1 | withdrawn | Apr 6, 2021 | Stanford University | Business Decision | Sponsor / business decision |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2018 | ADC Therapeutics S.A. | Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity.… | Other (stated, no rule matched) |
| NCT05471401 | GI Organ Tracking Via Balloon Applicators | N/A | withdrawn | Jul 22, 2022 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT04315883 | Yttrium-90 (TARE-Y90) in Children, Adolescents, and Young Adults With Liver Tumors | — | terminated | Mar 20, 2020 | Nemours Children's Clinic | PI left organization and discontinued study | Investigator |
| NCT04584775 | Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care | N/A | withdrawn | Oct 14, 2020 | Medical University of Graz | Covid19 Pandemia | COVID-19 / pandemic |
| NCT04843306 | Breath-Hold Technique for Pancreatic Stereotactic Body Radiation Therapy (SBRT) Patients | N/A | terminated | Apr 13, 2021 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Technical difficulties that were not able to be resolved. | Other (stated, no rule matched) |
| NCT04541173 | Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable… | Phase 2 | terminated | Sep 9, 2020 | Aiwu Ruth He, MD | Due to slow accrual. | Enrollment / accrual |
| NCT03450018 | A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects…(SLC-0111-17-01) | Phase 1 / Phase 2 | terminated | Mar 1, 2018 | British Columbia Cancer Agency | Changing treatment landscape: The availability of nab-paclitaxel with gemcitabine in the… | Enrollment / accrual |
| NCT03773302 | Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2… | Phase 3 | terminated | Dec 12, 2018 | QED Therapeutics, a BridgeBio company | The sponsor has decided to close the study due to the discontinuation of infigratinib development… | Safety / toxicity |
| NCT04088188 | Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of… | Phase 1 | terminated | Sep 12, 2019 | Academic and Community Cancer Research United | Low accrual | Enrollment / accrual |
| NCT04390243 | Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a… | Phase 2 | terminated | May 15, 2020 | Academic and Community Cancer Research United | Slow accrual | Enrollment / accrual |
| NCT02452970 | RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration…(EPIC) | Phase 2 | terminated | May 25, 2015 | EpicentRx, Inc. | Poor enrollment and adverse event experiences in the limited population | Safety / toxicity |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | Phase 1 | terminated | Sep 29, 2021 | Pfizer | The study was terminated by the Sponsor due to business decision and not due to any safety concerns… | Safety / toxicity |
| NCT06341725 | EUS Role in Non-metastatic Pancreatic Adenocarcinoma Lymph Nodes Staging | — | terminated | Apr 2, 2024 | Paolo Giorgio Arcidiacono, MD | no patients with inclusion criteria | Other (stated, no rule matched) |
| NCT03958669 | Fingerprint Characterization Tyrosine Kinase Inhibitors in Advanced HCC(e:Med-HCC-2) | — | terminated | May 22, 2019 | University Hospital Tuebingen | Slow recruitment due to COVID-19 pandemic and several newly approved treatment options | COVID-19 / pandemic |
| NCT02762266 | Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or… | Phase 3 | terminated | May 4, 2016 | Stanford University | Business decision - funding | Funding |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME… | Phase 1 | terminated | Mar 18, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT05292443 | Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated… | — | withdrawn | Mar 23, 2022 | Geneplus-Beijing Co. Ltd. | No participants were enrolled | Enrollment / accrual |
| NCT03812562 | Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical… | Early Phase 1 | terminated | Jan 23, 2019 | Northwestern University | Lack of funding | Funding |
| NCT03376659 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or… | Phase 1 / Phase 2 | terminated | Dec 18, 2017 | Georgetown University | Study closed due to lack of enrollment. | Enrollment / accrual |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | Phase 1 | terminated | Jul 18, 2019 | Kite, A Gilead Company | The sponsor finds the risk/benefit analysis unfavorable and has terminated the study. | Other (stated, no rule matched) |
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | Early Phase 1 | withdrawn | Feb 14, 2022 | OHSU Knight Cancer Institute | Withdrawn due to a change in therapeutic interventions. | Other (stated, no rule matched) |
| NCT03397342 | MRI Only Radiation Therapy With CPAP | N/A | terminated | Jan 12, 2018 | Albert Einstein College of Medicine | Study terminated prematurely well short of enrollment target. Only 5 health participants were… | Enrollment / accrual |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and… | Phase 1 / Phase 2 | terminated | Feb 6, 2018 | Cellestia Biotech AG | business reason | Sponsor / business decision |
| NCT00320918 | Chart Review: Unresectable/Metastatic Cholangiocarcinoma Treated With Irinotecan,… | — | terminated | May 3, 2006 | University of New Mexico | This was a Chart Review only and was entered in the system in error. | Other (stated, no rule matched) |
| NCT04046887 | Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With… | Phase 1 | terminated | Aug 6, 2019 | Patrick Joseph Loehrer Sr. | Unable to proceed due to Neulasta difficulties and other complications. | Other (stated, no rule matched) |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Phase 1 | terminated | Jan 28, 2020 | Atreca, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | Phase 1 | terminated | Dec 5, 2019 | University of Florida | Sponsor terminated | Other (stated, no rule matched) |
| NCT05514912 | Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without… | Phase 2 | withdrawn | Aug 25, 2022 | Emory University | PI has decided to terminate this study due to study supporter pulling support on this study. | Other (stated, no rule matched) |
| NCT04870034 | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive… | Early Phase 1 | withdrawn | May 3, 2021 | Roswell Park Cancer Institute | Issues recruiting | Enrollment / accrual |
| NCT03525392 | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in… | Phase 1 | terminated | May 15, 2018 | Ipsen | Due to agreement to transfer rights for IPN01087 to an external partner, not due to safety concerns | Safety / toxicity |
| NCT05193604 | A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects… | Phase 1 | terminated | Jan 18, 2022 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Terminated due to the adjustment of sponsor's development strategies and pipeline. | Sponsor / business decision |
| NCT02802124 | Carbon Ion Radiotherapy for the Treatment of Chinese Hepatocellular Carcinoma | N/A | terminated | Jun 16, 2016 | Shanghai Proton and Heavy Ion Center | For tumor locates away from GI the planned enrolled patient had been completed, but for tumor… | Enrollment / accrual |
| NCT05184283 | Utilization of MAsS in Patients Undergoing LT for HCC | — | terminated | Jan 11, 2022 | Columbia University | Discontinued by Amra Medical due to funding. | Funding |
| NCT05702385 | Clinical Utility Study for Exo-PDAC | N/A | withdrawn | Jan 27, 2023 | Qure Healthcare, LLC | The study sponsor did not wish to proceed with the study | Other (stated, no rule matched) |
| NCT01897454 | Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable… | Phase 2 | terminated | Jul 12, 2013 | Albert Einstein College of Medicine | Study was terminated due to slower than anticipated accrual | Enrollment / accrual |
| NCT03867370 | Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable… | Phase 1 / Phase 2 | terminated | Mar 8, 2019 | Shanghai Junshi Bioscience Co., Ltd. | Enrollment is over, the study was completed | Enrollment / accrual |
| NCT05641922 | Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of…(PANORAMA2) | N/A | withdrawn | Dec 8, 2022 | Techsomed Medical Technologies LTD | Withdrawn by Sponsor | Other (stated, no rule matched) |
| NCT01690715 | Prognostic Value Related to the Presence of Thrombosis or Portal Vein Invasion in…(HSL2012-06) | — | terminated | Sep 24, 2012 | Hospital Sirio-Libanes | There was recruted subject | Other (stated, no rule matched) |
| NCT04329949 | Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic…(RELIANT) | Phase 3 | terminated | Apr 1, 2020 | Corcept Therapeutics | The independent data monitoring committee found no safety issues, however the observed response… | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 9, 2024source: clinicaltrials